Lifeline Biotechnologies, Inc. Expands Testing Worldwide to Improve First Warning System™

TIME Article Examines the Changing Face of Breast Cancer

RENO, Nev.--(BUSINESS WIRE)--Lifeline Biotechnologies, Inc. (Pink Sheets: LLBT) today announced that the Company has expanded worldwide to continue testing the First Warning System™ technology, which is designed to assist in the detection of breast cancer. In 2008, Lifeline expects to be testing patients in Singapore at a hospital associated with Nanyang Technical University, and the results will be used to further the improvement of the First Warning System™.

In a recent TIME article, The Changing Face of Breast Cancer, by 2020, 70 percent of all breast cancer cases worldwide will be in developing countries. In relation to Caucasian women, Asian women tend to have denser breast tissue, and many studies show that dense tissue is up to five times as likely to develop malignancies. The article also states that such tissue can conceal the disease since both tumors and healthy tissue may show up white on a mammogram. In many developing countries, women tend to ignore signs of breast cancer because they simply do not want to talk about it or they cannot afford the consequences.

“This article provides us with an insider view on women and breast cancer in other countries, specifically Asia. Lifeline wants to target women on a worldwide basis and use our test results from Singapore to ensure that the First Warning System™ is as comprehensive and accurate as possible so that it can assist in the detection of breast cancer in the early stages,” stated Jim Holmes, CEO of Lifeline Biotechnologies, Inc.

To read the TIME article in its entirety, visit: http://www.time.com/time/specials/2007/0,28757,1666089,00.html.

About Lifeline Biotechnologies, Inc:

Lifeline Biotechnologies, Inc. is an innovative medical technology company that is committed to assisting in the early detection of breast cancer. The Company is focused on completing the development of the First Warning System™, designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: the development of the First Warning System™, the completion of clinical trials and FDA pre-marketing clearance.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact:

Lifeline Biotechnologies, Inc.
Investor Relations 
1-886-THE APPL(E)
www.lbti.com

Source: Lifeline Biotechnologies, Inc.